Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
Uuk1bDb90mtYpSh8